Medipharm Labs Shares Owned By Insiders vs. Price To Book

LABS Stock  CAD 0.07  0.01  7.14%   
Based on Medipharm Labs' profitability indicators, Medipharm Labs Corp may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Medipharm Labs' ability to earn profits and add value for shareholders. As of the 14th of December 2024, Price To Sales Ratio is likely to drop to 0.68. In addition to that, Days Sales Outstanding is likely to drop to 61.52. At this time, Medipharm Labs' Total Other Income Expense Net is very stable compared to the past year. As of the 14th of December 2024, Net Interest Income is likely to grow to about 498.8 K, while Accumulated Other Comprehensive Income is likely to drop about 15.8 M.
For Medipharm Labs profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Medipharm Labs to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Medipharm Labs Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Medipharm Labs's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Medipharm Labs Corp over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
Please note, there is a significant difference between Medipharm Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Medipharm Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medipharm Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Medipharm Labs Corp Price To Book vs. Shares Owned By Insiders Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Medipharm Labs's current stock value. Our valuation model uses many indicators to compare Medipharm Labs value to that of its competitors to determine the firm's financial worth.
Medipharm Labs Corp is currently regarded as number one stock in shares owned by insiders category among its peers. It also is currently regarded as number one stock in price to book category among its peers fabricating about  0.13  of Price To Book per Shares Owned By Insiders. The ratio of Shares Owned By Insiders to Price To Book for Medipharm Labs Corp is roughly  7.51 . As of the 14th of December 2024, Price To Book Ratio is likely to drop to 0.42. Comparative valuation analysis is a catch-all model that can be used if you cannot value Medipharm Labs by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Medipharm Labs' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Medipharm Price To Book vs. Shares Owned By Insiders

Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Medipharm Labs

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
4.45 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Medipharm Labs

P/B

 = 

MV Per Share

BV Per Share

 = 
0.59 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Medipharm Price To Book Comparison

Medipharm Labs is currently under evaluation in price to book category among its peers.

Medipharm Labs Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Medipharm Labs, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Medipharm Labs will eventually generate negative long term returns. The profitability progress is the general direction of Medipharm Labs' change in net profit over the period of time. It can combine multiple indicators of Medipharm Labs, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income29.5 M15.8 M
Operating Income-18.9 M-19.8 M
Net Loss-13.1 M-13.7 M
Income Before Tax-13.4 M-14 M
Net Loss-27 M-28.3 M
Net Loss-13.1 M-13.7 M
Total Other Income Expense Net5.5 M5.8 M
Income Tax Expense-276 K-262.2 K
Net Interest Income475 K498.8 K
Interest Income840 K798 K
Change To Netincome16.2 M8.1 M
Net Loss(0.04)(0.04)
Income Quality 0.94  0.99 
Net Income Per E B T 0.98  0.70 

Medipharm Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Medipharm Labs. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Medipharm Labs position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Medipharm Labs' important profitability drivers and their relationship over time.

Use Medipharm Labs in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medipharm Labs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medipharm Labs will appreciate offsetting losses from the drop in the long position's value.

Medipharm Labs Pair Trading

Medipharm Labs Corp Pair Trading Analysis

The ability to find closely correlated positions to Medipharm Labs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medipharm Labs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medipharm Labs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medipharm Labs Corp to buy it.
The correlation of Medipharm Labs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medipharm Labs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medipharm Labs Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medipharm Labs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Medipharm Labs position

In addition to having Medipharm Labs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large Value Funds Thematic Idea Now

Large Value Funds
Large Value Funds Theme
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Value Funds Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Medipharm Stock

To fully project Medipharm Labs' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Medipharm Labs Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Medipharm Labs' income statement, its balance sheet, and the statement of cash flows.
Potential Medipharm Labs investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Medipharm Labs investors may work on each financial statement separately, they are all related. The changes in Medipharm Labs's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Medipharm Labs's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.